Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03125187Phase 1Suspended

Study With Heparin Sodium in Intravenous Administration

Role: lead

NCT03120130Phase 1Suspended

Study of Amblyomin-X in Advanced Solid Tumor

Role: lead

NCT03113084Phase 1Suspended

Study With Heparin Sodium in Subcutaneous Administration

Role: lead

NCT01480778Phase 3Completed

Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.

Role: collaborator

All 4 trials loaded